Speaker Profile

Director, Precision Medicine Initiatives, LUNGevity Foundation

Nikki focuses on accelerating access to precision medicine, especially biomarker testing, for lung cancer patients. Nikki came into patient advocacy from multiple roles at pharmaceutical and diagnostic companies including Genentech, Novartis, and Grifols where she collaborated with patient advocacy groups across different cancer types and other diseases in the US and around the world. This has given her a great vantage point to see the true value of patient advocacy-led multi-stakeholder efforts for jump-starting conversations. She believes that patient advocacy organizations play an essential role in convening different players from government to providers, payers, and industry and leading or contributing to critical work that has long lasting impact on patient care.

 Session Abstract – PMWC 2022 Silicon Valley

Track 3, June 28

Precision medicine is among the key contributors in progressing cancer survivorship. However, biomarker testing, which is critical to enabling precision medicine treatments, is below guideline recommendations due to various factors. The session will discuss these barriers, as well as bringing tangible and sustainable solutions to patients with cancer through collaboration.